Allworth Financial LP Acquires 332 Shares of Natera, Inc. $NTRA

Allworth Financial LP raised its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 29.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,453 shares of the medical research company’s stock after buying an additional 332 shares during the period. Allworth Financial LP’s holdings in Natera were worth $245,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of NTRA. Bank of Jackson Hole Trust bought a new stake in shares of Natera during the 1st quarter valued at $29,000. TCTC Holdings LLC lifted its position in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 106 shares during the period. Hilltop National Bank purchased a new stake in Natera in the second quarter worth about $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in shares of Natera in the second quarter worth about $36,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent research reports. Barclays boosted their price objective on Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Evercore ISI upped their price target on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. raised their price objective on shares of Natera from $210.00 to $240.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. Fifteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $216.65.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00. Following the sale, the insider directly owned 112,061 shares in the company, valued at $22,255,314.60. This represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 1,867 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total value of $355,924.88. Following the completion of the sale, the chief financial officer directly owned 64,126 shares of the company’s stock, valued at $12,224,980.64. The trade was a 2.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 223,336 shares of company stock valued at $42,990,633 over the last quarter. 5.63% of the stock is owned by corporate insiders.

Natera Price Performance

NASDAQ:NTRA opened at $206.04 on Tuesday. The company has a market cap of $28.44 billion, a price-to-earnings ratio of -89.97 and a beta of 1.74. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $212.21. The stock’s 50 day simple moving average is $182.28 and its two-hundred day simple moving average is $166.14.

Natera (NASDAQ:NTRA) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same period last year, the business posted ($0.26) earnings per share. The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.